INTRODUCTION AND OBJECTIVES:
To report medium-term oncological outcomes in patients receiving primary focal treatment with HIFU for PCa.
METHODS: Consecutive men treated by means of primary focal HIFU for PCa at two centres by 6 treating clinicians were prospectively collected. Patients were submitted to either a focal ablation or hemiablation using HIFU (Sonablate 500). The primary objective of the study was to assess medium-term oncological outcomes defined as overall survival, freedom from biopsy failure, freedom from any further treatment and freedom from radical treatment after focal HIFU. The secondary objective was to evaluate the changes in pathological features among patients treated by means of focal HIFU over time. We finally assessed the relationship between year of surgery and 5-years retreatment probability RESULTS: One thousand and thirty-two men treated between November 2005 and October 2017 were assessed. The median age was 65 yrs and median prostate-specific antigen was 7 ng/ml. The majority of patients had Gleason score of 3þ4 (63%). Median followup was 36 months (IQR: 14-64). The overall survival at 24, 60 and 96 months was 99%, 97% and 97%, respectively. Freedom from biopsy failure, defined as absence of Gleason 3þ4 disease, was 84%, 64% and 54% at 24, 60 and 96 months. Freedom from any further treatment was 85, 59 and 46% at 24, 60 and 96 months, respectively. Roughly 70% of patients retreated received a reapplication of focal approach. Freedom from radical treatment was 98%, 91% and 81% at 24, 60 and 96 months. During the study period we have seen an increase in the proportion of patients undergoing focal HIFU with Gleason 3þ4 disease and with T2 mpMRI staged disease. Finally, we report a reduction over time in the proportion of men undergoing re-treatment within 5-years of first treatment.
CONCLUSIONS: Focal therapy for PCa using HIFU as energy source is a feasible therapeutic strategy with acceptable survival and oncological results at medium term, at least for men with up to intermediate risk disease, that appears improving over time. Re-do focal treatment is a feasible technique whose functional and oncological outcomes are under longer term evaluation.
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MP78-06 MEDIAN 5-YEAR ONCOLOGICAL OUTCOMES OF SALVAGE HIGH INTENSITY FOCUSED ULTRASOUND FOR PROSTATE CANCER RECURRENCES AFTER PRIMARY RADIOTHERAPY
Shiva Nair*, London, Canada; Max Peters, Jochem van der Voort van Zyp, Marieke van Son, Utrecht, Netherlands; Joseph Chin, London, Canada INTRODUCTION AND OBJECTIVES: Recurrent prostate cancer after primary radiotherapy occurs despite dose escalation, especially in higher risk groups. Local recurrence/failure can be treated using salvage therapy, thereby deferring subsequent non-curative systemic treatments. Tumor control results of salvage high intensity focused ultrasound (HIFU) at median 5 years follow-up are reported.
METHODS: From April 2006 until March 2017, patients with histologically conformed recurrent prostate cancer were treated using whole-gland salvage HIFU (Sonablate, whole gland). Bone scan and CT (abdomen and pelvis) were negative for clinical metastatic disease. Data before salvage HIFU was collected to predict oncological outcomes. This included pre-radiation Gleason score and PSA, Charlson comorbidity index, age, pre-salvage PSA, pre-salvage prostate volume, pre-salvage use of ADT and PSA nadir post salvage. Overall survival (OS), prostate cancer specific survival (PCSS), metastases free survival (MFS) were calculated using the Kaplan-Meier method. After multiple imputation to account for missing data, Cox-regression was used to assess predictive factors for OS. Local ethic board approval was obtained for data collection and analysis.
RESULTS: 87 patients with complete data on salvage HIFU were analyzed. Median follow-up was 65 months (interquartile range, . Median age before salvage was 71 years (IQR 66-74), median PSA pre-salvage 3.8 ng/ml (IQR 2.3-5.1), median PSA nadir post HIFU 0.44 (IQR 0.04-1.41), median prostate volume 23.2cc . Most patients had Charlson comorbidity score 4 (31%), 5 (33.3%) or 6 (18.4%). 14.9% had primary Gleason 6 before radiation and 78.2% Gleason 7 or greater. 21.8% used ADT pre-salvage HIFU (all discontinued post-HIFU). Five-year OS was 83% (CI 75-92), PCSS was 89% (CI 82-97) and MFS was 85% (CI 77-94). Pre-salvage PSA predicted overall mortality in univariate analysis (P < 0.0001), but not in multivariate analysis. 51 patients (58.6%) were ADT free at last follow up with a median time to ADT at 118 months .
CONCLUSIONS: Salvage HIFU can achieve high OS, PCSS and MFS in the medium term in properly selected patients with radiorecurrent prostate cancer. Prostate cancer radio-recurrence does not and should not automatically lead to ADT use. Urologists should include this in the option discussion for localized radiorecurrent disease, especially in men who may not be suitable for salvage radical prostatectomy due to comorbidities.
